Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 9/20 | 0.38 |
| ▸ | PTGER3 | P43115 | 9/20 | 0.38 |
| ▸ | PTGER2 | P43116 | 9/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 7/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL214606 | 0.87 | RECQL (0.38) | RECQL | |
| SCHEMBL214605 | 0.87 | RECQL (0.38) | RECQL | |
| SCHEMBL213563 | 0.85 | AKR1C3 (0.38) | — | |
| SCHEMBL213562 | 0.85 | AKR1C3 (0.38) | — | |
| SCHEMBL215320 | 0.81 | MCL1 (0.36) | — | |
| SCHEMBL214578 | 0.80 | MCL1 (0.35) | — | |
| SCHEMBL213113 | 0.79 | NR1H4 (0.43) | — | |
| SCHEMBL214486 | 0.79 | RECQL (0.35) | RECQLMEN1KMT2A | |
| SCHEMBL214485 | 0.79 | RECQL (0.35) | RECQLMEN1KMT2A | |
| SCHEMBL214579 | 0.79 | RORC (0.35) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082653-A1 | Remedies for depression containing ep1 antagonist as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082653-A1 | Remedies for depression containing ep1 antagonist as the active ingredient | PTGER1, PTGER2, PTGS1 | PTGER4 5/4885PTGER3 6/4885PTGER2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.